Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of HMI-115 in male androgenetic alopecia
CTR20232350Phase 2Completed
- Sponsor
- HopeMed
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HMI-115 in androgenetic alopecia (AGA), sponsored by HopeMed. Started Aug 2023; status: completed.
02
Drugs
HMI-115
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20232350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232350.